Skip to main content
Daniel Lindner, MD, General Surgery, Cleveland, OH

DanielJLindnerMDPhD

General Surgery • Cleveland, OH

Assistant Professor, Molecular Medicine, Case Western Reserve University School of Medicine

Join to view full profile

Dr. Lindner is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Lindner's full profile

Already have an account?

  • Office

    Cleveland Clinic Main Campus
    9500 Euclid Avenue
    Cleveland, OH 44195
    Phone+1 216-445-0548

Education & Training

  • Georgetown University School of Medicine
    Georgetown University School of MedicineClass of 1981

Publications & Presentations

PubMed

Abstracts/Posters

  • Hypomethylating Agent 5-Azacytidine Sensitizes Peripheral T-Cell Lymphoma to SLAMF7-Targeting Therapeutic Antibody, Elotuzumab
    Daniel Lindner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • TET Dioxygenase Inhibition As a Therapeutic Strategy in TET2 Mutant Myeloid Neoplasia
    Daniel Lindner, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Development of a Novel Class of Agents Targeting the RNA-Splicing Machinery in Myeloid Malignancies 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • The Kindlin2-p53-SerpinB2 Signaling Axis Is Required for Cellular Senescence in Breast Cancer
    The Kindlin2-p53-SerpinB2 Signaling Axis Is Required for Cellular Senescence in Breast CancerJuly 15th, 2020
  • CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with the Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D.
    CytoDyn Initiates Pre-Clinical Study of Leronlimab (PRO 140) to Prevent NASH with the Cleveland Clinic’s Dr. Daniel J. Lindner, M.D., Ph.D.May 13th, 2019
  • ASH 2018: Dec 1-4
    ASH 2018: Dec 1-4December 1st, 2017
  • Join now to see all

Grant Support

  • Nitrosylcobalamin - A Novel Chemotherapeutic AgentNational Cancer Institute2004–2007
  • Inositol Hexakisphosphate Kinase 2:Apoptosis RegulatorNational Cancer Institute2004–2006
  • Inositol Hexakisphosphate Kinase 2:Apoptosis RegulatorNational Cancer Institute2003

Dr. Daniel Lindner, Dr. Daniel Lindner, MD, Dr. D Lindner, Dr. Daniel J Lindner